Updating the stock performances of the 13 constituents in our Pure-Play Marijuana and Psychedelic Compounds-Based Drug Stocks Index: up last week but still down 32% YTD.

This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.

This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a total of 100 such companies. 

There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index, which is now -65.9% from its 2021 highs. Here are the details for each constituent.

In the past week, of the 41 psychedelic drug stocks that trade on the various North American stock exchanges only nine went up in price, while 31 went down and one had no change.